1887
Review articles Open Access
Like 0

Abstract

In 2010, increased febrile convulsions (FC) occurred after administration of inactivated trivalent influenza vaccine (TIV) in Australia. We systematically reviewed the rates of fever, FC and serious adverse events (SAEs) after TIV, focussing on published and unpublished clinical trial data from 2005 to 2012, and performed meta-analysis of fever rates. From 4,372 records in electronic databases, 18 randomised controlled trials (RCTs), 14 non-randomised clinical trials, six observational studies and 12 registered trials (five RCTs and seven non-randomised) were identified. In published RCTs, fever?≥?38?°C rates after first dose of non-adjuvanted TIV were 6.7% and 6.9% for children aged 6-35 months and?≥?3 years, respectively. Analysis of RCTs by vaccine manufacturer showed pooled fever estimates up to 5.1% with Sanofi or GlaxoSmithKline vaccines; bioCSL vaccines were used in two non-randomised clinical trials and one unpublished RCT and were associated with fever in 22.5-37.1% for children aged 6-35 months. In RCTs, FCs occurred at a rate of 1.1 per 1,000 vaccinated children. While most TIVs induced acceptably low fever rates, bioCSL influenza vaccines were associated with much higher rates of fever in young children. Future standardised study methodology and access to individual level data would be illuminating. .

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES2015.20.24.21159
2015-06-18
2024-03-19
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES2015.20.24.21159
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/20/24/art21159-en.htm?itemId=/content/10.2807/1560-7917.ES2015.20.24.21159&mimeType=html&fmt=ahah
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error